Latrovin (Atorvastatin)

Atorvastatin blocks the enzyme HMG‑CoA reductase in the liver, which is essential for cholesterol synthesis. This reduction in hepatic cholesterol prompts the liver to increase LDL‑receptor expression, enhancing removal of LDL cholesterol from the bloodstream and lowering overall plasma cholesterol.

The specific dose of Latrovin is determined by the prescribing clinician based on the patient’s cholesterol levels, cardiovascular risk profile, and tolerance. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Statins, including atorvastatin, are generally contraindicated during pregnancy because of potential fetal harm. Use while breastfeeding is not recommended unless the benefits clearly outweigh the risks, and this decision should be made by a healthcare professional.

To place an order, submit an enquiry on the Latrovin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Atorvastatin is a high‑potency statin that typically provides greater LDL‑cholesterol reduction than lower‑intensity statins such as pravastatin or simvastatin. Compared with non‑statin agents, it has a well‑established evidence base for cardiovascular risk reduction, though individual response and tolerance may vary.

Latrovin tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Do not store in areas of high humidity or extreme heat.

Latrovin is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water and follow any specific timing instructions provided by the healthcare professional.

The most serious adverse reactions include rhabdomyolysis, a severe muscle breakdown that can lead to kidney failure, and significant liver injury. Patients should report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction such as jaundice promptly.

Latrovin should be avoided in individuals with active liver disease, unexplained persistent elevations of hepatic enzymes, known hypersensitivity to atorvastatin or any excipients, and in pregnant or nursing women unless a physician determines that the benefits outweigh the risks.